OVERVIEW
This policy documents the coverage determination for Auditory Brain Stem Implant. The auditory brain
stem implant (ABI) is a device designed to restore some hearing in people with neurofibromatosis type 2
(NF2) who are rendered deaf by bilateral removal of the characteristic neurofibromas involving the auditory
nerve.

PRIOR AUTHORIZATION
Not Applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial

Use of a unilateral auditory brain stem implant (using surface electrodes on the cochlear nuclei) is considered
medically necessary in patients with neurofibromatosis type 2 (diagnosis code 237.72), 12 years of age or
older, who are rendered deaf due to bilateral resection of neurofibromas of the auditory nerve.

An auditory brain stem implant is considered not medically necessary for all other conditions including
non-neurofibromatosis type 2 indications as there are inadequate data to permit scientific conclusions
regarding its efficacy.

Bilateral use of an auditory brain stem implant is considered not medically necessary as there are inadequate
data to permit scientific conclusions regarding its efficacy.

Penetrating electrode auditory brainstem implant (PABI) is considered not medically necessary as there are
inadequate data to permit scientific conclusions regarding its efficacy.

MEDICAL CRITERIA
Not Applicable

BACKGROUND
The auditory brain stem implant (ABI) is a device designed to restore some hearing in people with
neurofibromatosis type 2 who are rendered deaf by bilateral removal of the characteristic neurofibromas
involving the auditory nerve.

The device consists of an externally worn speech processor that provides auditory information to an electrical
signal that is transferred to a receiver/stimulator that is implanted in the temporal bone. The receiver
stimulator is, in turn, attached to an electrode array that is implanted on the surface of the cochlear nerve in
the brain stem, thus bypassing the inner ear and auditory nerve. The electrode stimulates multiple sites on the
cochlear nucleus, which is then processed normally by the brain.

One device has received approval by the U.S. Food and Drug Administration (FDA) for auditory brain stem
implantation, the Nucleus 24® Auditory Brainstem Implant System (Cochlear Corporation). The speech
processor and receiver are similar to the devices used in cochlear implants; the electrode array placed on the
Brainstem is the novel component of the device. The device is indicated for individuals 12 years of age or older who have been diagnosed with neurofibromatosis type 2 (NF2).

The available evidence for unilateral use of ABI devices in patients with NF2 is sufficient to demonstrate improvements in net health outcomes. Therefore, the policy statement indicates an auditory brainstem implant may be considered medically necessary in this condition.

ABIs hold promise for select patients with bilateral complete cochlear aplasia and demonstrated absence of a cochlear nerve on imaging and electrophysiologic testing. In patients with other non-NF2 conditions, ABIs have not demonstrated hearing benefits over cochlear implants. However, studies on ABIs for non-NF2 conditions are limited, with small numbers of patients and insufficient data to make scientific conclusions. Given the lack of both high-quality evidence and FDA approval, ABI for non-NF2 conditions and bilateral ABI are considered medically unnecessary. Penetrating electrode auditory brainstem implant is also considered medically unnecessary because the very limited evidence available is insufficient to draw conclusions on health outcomes.

**COVERAGE**
Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable Services Not Medically Necessary coverage.

**CODING**
**BlueCHiP for Medicare and Commercial**

The following codes are covered if medically necessary for patients 12 years of age older with a diagnosis of Neurofibromatosis type 2:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>92640</td>
<td>Diagnosis Code: 237.72</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2235</td>
<td>Diagnosis Code: Q85.02</td>
</tr>
<tr>
<td>ICD 9</td>
<td></td>
<td>Diagnosis Code: 237.72</td>
</tr>
<tr>
<td>ICD10</td>
<td></td>
<td>Diagnosis Code: Q85.02</td>
</tr>
</tbody>
</table>

**RELATED POLICIES**
None

**PUBLISHED**
- Provider Update Oct 2014
- Provider Update May 2013
- Provider Update Apr 2012
- Provider Update May 2011
- Provider Update May 2010

**REFERENCES**


4. Sanna M, Di Lella F, Guida M et al. Auditory brainstem implants in NF2 patients: results and review of
the literature. Otol Neurotol 2012; 33(2):154-64


